Sunday, 05 December 2021

Sihuan Pharm achieves new grant approval

28 May 2019 | News

Grant approval for this exclusive formulation enriches the anti-infective drug's production and contribute to the antibiotic intravenous solution market

Photo credit: prnewswire

Photo credit: prnewswire

Sihuan Pharmaceutical Holdings Group Ltd., the largest cardio-cerebral vascular (CCV) drug manufacturer in China's prescription drug market, announced its grant approval for "non-PVC solid-liquid double chamber bag for ceftazidime/sodium chloride injection”. Jointly developed by this Group and its associated company Beijing Ruiye Drugs Manufacture Co. Ltd., the drug registration approval is granted by the National Medical Products Administration (NMPA) of the People's Republic of China. All the ceftazidime currently approved for production in China are powder injection. The Group is the first company that has been granted drug registration approval for "non-PVC solid-liquid double chamber bag for ceftazidime/sodium chloride injection" in China.

Non-PVC solid-liquid double chamber infusion soft bag formulation avoids secondary contamination in the dispensing process caused by microorganisms and particles. It has been recognized as the safest and most convenient infusion product and is considered as one of the technologically advanced new formulations of the intravenous solution with great development potential in the pharmaceutical industry. Non-PVC soft bag infusion products are the mainstream in the intravenous solution market and are currently manufactured only in the United States and Japan.

The Product is an exclusive formulation of ceftazidime/sodium chloride injection which is a semi-synthetic third-generation cephalosporins antibiotics used to treat multiple infections of immunodeficiency patients caused by multiple resistant gram-negative bacilli.

Beijing Ruiye has been dedicated to the research and development of the formulation since 2005 by introducing Japan's cutting-edge technology and was the first and only in China that has been granted drug registration approval by the NMPA. This Formulation utilizes specific processes and uses non-PVC multi-layer co-extrusion film as packaging materials and encloses the drug and solvent injection into the two chambers of the same packaging, which are separated by empty solder. Before infusion, the user only needs to squeeze the bottom of the chambers making them connected, allowing the drug powder and the solvent injection to be mixed with each other.

According to MENET database, the sales of antibacterial drugs for full application in 2017 was RMB128.73 billion. Among which, the sales of cephalosporins was RMB67.02 billion, accounting for 52.3% of the market share of antibacterial drugs for the full application. Currently, all the ceftazidime currently approved for production in China are powder injection which achieved annual sales of RMB4.52 billion, accounting for 6.7% of the market share of cephalosporins. The launch of the Group's solid-liquid double chamber bag product is expected to replace some of the existing products and have a promising market prospect.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account